Suppr超能文献

Musashi-2 在侵袭性套细胞淋巴瘤中的致瘤作用。

Tumorigenic role of Musashi-2 in aggressive mantle cell lymphoma.

机构信息

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

出版信息

Leukemia. 2023 Feb;37(2):408-421. doi: 10.1038/s41375-022-01776-x. Epub 2022 Dec 12.

Abstract

SOX11 overexpression has been associated with aggressive behavior of mantle cell lymphomas (MCL). SOX11 is overexpressed in embryonic and cancer stem cells (CSC) of some tumors. Although CSC have been isolated from primary MCL, their relationship to SOX11 expression and contribution to MCL pathogenesis and clinical evolution remain unknown. Here, we observed enrichment in leukemic and hematopoietic stem cells gene signatures in SOX11+ compared to SOX11- MCL primary cases. Musashi-2 (MSI2) emerged as one of the most significant upregulated stem cell-related genes in SOX11+ MCLs. SOX11 is directly bound to the MSI2 promoter upregulating its expression in vitro. MSI2 intronic enhancers were strongly activated in SOX11+ MCL cell lines and primary cases. MSI2 upregulation was significantly associated with poor overall survival independently of other high-risk features of MCL. MSI2 knockdown decreased the expression of genes related to apoptosis and stem cell features and significantly reduced clonogenic growth, tumor cell survival and chemoresistance in MCL cells. MSI2-knockdown cells had reduced tumorigenic engraftment into mice bone marrow and spleen compared to control cells in xenotransplanted mouse models. Our results suggest that MSI2 might play a key role in sustaining stemness and tumor cell survival, representing a possible novel target for therapeutic interventions in MCL.

摘要

SOX11 过表达与套细胞淋巴瘤(MCL)的侵袭性行为有关。SOX11 在一些肿瘤的胚胎和癌症干细胞(CSC)中过表达。尽管已经从原发性 MCL 中分离出 CSC,但它们与 SOX11 表达的关系以及对 MCL 发病机制和临床演变的贡献仍不清楚。在这里,我们观察到与 SOX11-相比,SOX11+MCL 原代病例中白血病和造血干细胞基因特征富集。Musashi-2(MSI2)是 SOX11+MCL 中上调最显著的干细胞相关基因之一。SOX11 直接结合 MSI2 启动子,在体外上调其表达。SOX11+MCL 细胞系和原代病例中 MSI2 内含子增强子被强烈激活。MSI2 的上调与其他 MCL 的高危特征无关,与总生存不良显著相关。MSI2 敲低降低了与凋亡和干细胞特征相关的基因的表达,并显著降低了 MCL 细胞的克隆生长、肿瘤细胞存活和化疗耐药性。与对照细胞相比,MSI2 敲低细胞在异种移植小鼠模型中的致瘤性植入到小鼠骨髓和脾脏中的能力降低。我们的研究结果表明,MSI2 可能在维持干细胞特性和肿瘤细胞存活方面发挥关键作用,代表了治疗干预 MCL 的一个潜在新靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c34/9898029/489fdfca5a99/41375_2022_1776_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验